FY2024 Earnings Forecast for argenx Issued By HC Wainwright

argenx SE (NASDAQ:ARGX - Free Report) - Stock analysts at HC Wainwright upped their FY2024 EPS estimates for argenx in a report released on Tuesday, January 14th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $2.30 per share for the year, up from their previous estimate of $0.78. HC Wainwright currently has a "Buy" rating and a $717.00 target price on the stock. The consensus estimate for argenx's current full-year earnings is $2.17 per share. HC Wainwright also issued estimates for argenx's Q4 2024 earnings at $1.49 EPS, Q1 2025 earnings at $1.23 EPS, Q2 2025 earnings at $1.69 EPS, Q3 2025 earnings at $1.65 EPS, Q4 2025 earnings at $1.80 EPS, FY2025 earnings at $6.36 EPS, FY2026 earnings at $18.58 EPS, FY2027 earnings at $31.03 EPS, FY2028 earnings at $43.49 EPS and FY2029 earnings at $58.70 EPS.

Several other brokerages also recently issued reports on ARGX. Piper Sandler upped their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. Wedbush reiterated an "outperform" rating and issued a $655.00 target price on shares of argenx in a report on Tuesday, December 3rd. Oppenheimer reissued an "outperform" rating and set a $675.00 price target (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. Evercore ISI upped their price objective on shares of argenx from $675.00 to $706.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Finally, Guggenheim increased their price objective on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $658.39.

argenx Stock Performance

ARGX traded down $19.29 during midday trading on Friday, reaching $640.52. 483,293 shares of the company were exchanged, compared to its average volume of 312,661. The company has a market cap of $38.67 billion, a price-to-earnings ratio of -727.86 and a beta of 0.59. argenx has a one year low of $349.86 and a one year high of $678.21. The company's fifty day moving average price is $620.19 and its 200 day moving average price is $555.67.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same period in the previous year, the firm posted ($1.25) earnings per share.

Institutional Trading of argenx

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock valued at $220,000 after buying an additional 21 shares in the last quarter. Profund Advisors LLC grew its position in shares of argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after purchasing an additional 28 shares in the last quarter. Raymond James Trust N.A. raised its stake in shares of argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock valued at $268,000 after purchasing an additional 28 shares during the period. Wealth Alliance lifted its holdings in argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company's stock worth $270,000 after purchasing an additional 29 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its stake in argenx by 8.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company's stock worth $286,000 after purchasing an additional 43 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.